Lassa fever clinical course and setting a standard of care for future randomized trials: A protocol for a cohort study of Lassa-infected patients in Nigeria (LASCOPE)

Background: Lassa Fever (LF), is a severe viral disease prevalent in Western Africa. It is classified as a priority disease by the World Health Organization (WHO). Ribavirin is the recommended therapy despite weak evidence of its efficacy. Promising therapeutic agents are becoming available for eval...

ver descrição completa

Detalhes bibliográficos
Principais autores: Duvignaud, A, Jaspard, M, Etafo, IC, Serra, B, Abejegah, C, Gabillard, D, Doutchi, M, Alabi, JF, Adedokun, MA, Akinpelu, AO, Oyegunle, OO, Etafo, J, Dede, AO, Onyechi, MN, Ireneh, MU, Gbenga-Ayeni, O, Fadiminiyi, KG, Ehigbor, PI, Ouattara, E, Levy-Marchal, C, Karcher, S, N'guessan-Koffi, L, Ahyi, I, Amani, E, Diabaté, M, Siloué, B, Schaeffer, J, Augier, A, Ogbaini-Emovon, E, Salam, AP, Horby, P, Ahmed, LA, Günther, S, Adedosu, AN, Anglaret, X, Ayodeji, OO, Malvy, D
Formato: Journal article
Idioma:English
Publicado em: Elsevier 2020